Tag: programs

SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce the successful completion of dose level 1 for its first-in-human Phase I dose-escalation clinical trial (NCT05302037) (“ANGELICA Trial”) for four late stage cancer patients and is scheduled to start dose level 2 of the ANGELICA Trial in third quarter of 2025.

The Sleep Apnea Devices Market presents robust growth opportunities, especially in regions like North America and Europe where awareness, infrastructure, and reimbursement support are strong. However, high device costs and poor compliance rates remain critical hurdles. For successful market entry, companies must focus on product affordability, user comfort, and telemedicine integration. Expanding into Asia-Pacific with scalable, portable, and AI-enabled diagnostic tools offers a high-potential growth avenue, given the rising healthcare penetration. Strategic partnerships with local providers and government awareness programs will be key to unlocking untapped markets and gaining competitive advantage.

New York, N.Y., July 21, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced it will host its third fiscal quarter financial results and business update webcast on Thursday, August 14, 2025, at 5:00 p.m. ET.